SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

Gold is facing a sharp sell-off as a combination of a surging dollar, rising interest rate expectations, and broader liquidity concerns drives investors to exit precious metal positions. The community is actively debating whether this is a temporary shakeout that offers a buying opportunity for long-term holders or a more systemic shift that challenges gold's status as a traditional safe-haven asset during times of geopolitical tension.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing intense volatility as investors closely monitor geopolitical escalations in the Middle East, specifically threats surrounding the Strait of Hormuz and potential impacts on global energy supply chains. Market participants are actively debating the sustainability of current tech valuations and discussing whether the recent pullbacks represent a strategic buying opportunity or the beginning of a deeper market correction driven by macroeconomic uncertainty.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently under intense market pressure as investors weigh the impact of rising geopolitical tensions and crude oil price volatility against the company's ambitious, capital-intensive plans for in-house AI chip production. The community remains deeply divided, with bulls pointing to long-term synergies across Tesla, SpaceX, and xAI, while bears express skepticism over recent legal hurdles, ongoing delivery concerns, and the feasibility of Musk's aggressive technology roadmap.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is currently trending as investors grapple with extreme market volatility driven by escalating geopolitical tensions in the Middle East and the uncertainty surrounding impending policy deadlines. The community is sharply divided, with intense debate focused on whether these conditions signal an imminent market collapse or a temporary shakeout that will ultimately favor opportunistic buyers.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is facing intense downward pressure driven by a combination of broader market volatility and a persistent short-seller report from Muddy Waters, which has triggered aggressive trading from both retail bulls and institutional bears. The community remains deeply divided, with many long-term investors pointing to CEO Anthony Noto’s recent insider buying as a signal of fundamental strength, while bears emphasize the ongoing uncertainty surrounding the firm’s accounting practices and macro-economic headwinds.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta is facing downward pressure as investors express skepticism over the company's massive capital expenditures toward AI infrastructure and the recent decision to scale back its metaverse initiatives. Community sentiment is deeply divided, with some traders bracing for further volatility due to technical chart patterns and layoff rumors, while long-term investors maintain conviction in the stock's underlying fundamentals and growth potential.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending as investors digest a major breakthrough in EUV light source technology that could significantly boost chip production efficiency by 2030, alongside anticipation for upcoming earnings. The community remains focused on the company's long-term dominance as an essential 'pick and shovel' play for the ongoing AI infrastructure build-out.

United States Commodity Funds LLC - United States Natural Gas Fund

United States Natural Gas Fund, LP

United States Natural Gas Fund (UNG) is trending as traders navigate extreme volatility fueled by severe winter weather, supply disruptions, and significant geopolitical tensions in the Middle East. The community is actively debating the sustainability of these price spikes, with many weighing the impact of weather-driven demand against the potential for rapid supply normalization.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing intense community debate as investors reconcile stellar, AI-driven quarterly earnings with a sharp price pullback and broader market anxiety regarding the geopolitical conflict in the Middle East. While some traders are expressing frustration over the stock's volatility and short-term manipulation, many long-term holders are highlighting the company's valuation metrics and secular growth potential as a generational buying opportunity.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is facing significant downward pressure following its post-earnings rally, as investors grapple with broader geopolitical instability and concerns over high infrastructure spending. While the community remains deeply divided between those viewing the pullback as a strategic accumulation opportunity based on strong backlog growth and those concerned by persistent selling and technical weakness, sentiment is heavily influenced by intense debates over AI's long-term profitability versus potential overvaluation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages

ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven analysts that are covering the firm, Marketbeat Ratings reports. One...

Promising Biotech Stocks To Keep An Eye On - March 21st

Danaher, Vertex Pharmaceuticals, Moderna, United Therapeutics, ImmunityBio, argenex, and Medpace are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

ImmunityBio (NASDAQ:IBRX) Stock Price Down 4%  - Should You Sell?

ImmunityBio (NASDAQ:IBRX) Trading Down 4% - Time to Sell...

ImmunityBio Sees Unusually High Options Volume (NASDAQ:IBRX)

ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) was the recipient of unusually large options trading on Friday. Investors acquired 51,571 call options on the stock. This is an increase of 50...

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA in BCG-Unresponsive NMIBC with CIS Papillary Tumors

ImmunityBio, Inc. (NASDAQ: IBRX), today announced that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the Peoples Republic of China has granted...

<ul class="summary-bullets"><li>A record $5.7 trillion “triple witching” options expiry threatens to inject fresh swings into an already fragile market.</li><li>Markets remain on edge as escalating Middle East tensions fuel oil volatility.</li><li>SMCI stock tanks 20% in early pre-market trade on alleged Nvidia chip diversion to China.&nbsp;</li></ul>U.S. stock futures took a breather early Friday with investors parsing the latest developments in the Middle East. However, fresh Israeli strikes on Iran and risks around the Strait of Hormuz are keeping oil volatility in action.Traders will also be&nbsp; focusing on a historic options expiration. They are&nbsp; bracing for a staggering $5.7 trillion in notional options to expire today, which is reportedly the largest March expiry in Citigroup data going back to 1996.&nbsp; As of 4:00 a.m. ET on Friday, Dow futures rose 0.2%, S&amp;P futures gained 0.1%, the Nasdaq futures were flat with a positive bias, and Russell 2000 futures were up 0.3%.Caution prevails among the traders. Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, remained ‘extremely bearish, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has remained ‘bearish’ amid high trading volume.&nbsp;Trending Stocks To Watch Super Micro Computer (SMCI):&nbsp;The stock is on retail radar this morning after U.S. prosecutors charged three individuals, including a co-founder and a board member, in a scheme to smuggle Nvidia (NVDA) chips to China. Both companies have stressed on compliance in their statements.&nbsp;Nvidia (NVDA) &amp; Amazon (AMZN):&nbsp;Despite the SMCI scandal, Nvidia remains in focus following reports it will sell 1 million chips to Amazon by the end of 2027 as part of a massive cloud infrastructure deal. Amazon also boosted its logistics wing by acquiring the autonomous robotics startup Rivr.Meta (META): The company reportedly reversed its decision to shut down&nbsp;Horizon Worlds for Quest VR headsets, citing fan feedback.Tech stocks also remain in the spotlight on reports that the White House is expected to release a&nbsp;national AI regulatory framework in the coming days.&nbsp;Tesla (TSLA):&nbsp;The EV giant is back in focus as it doubles down on its solar and energy ambitions with a $2.9 billion China-linked expansion, while also nearing a potential rollout of its Full Self-Driving (FSD) software in Europe.FedEx (FDX): The stock is garnering retail attention following a Q3 earnings beat and a raised FY26 outlook. Analysts at Wells Fargo and JPMorgan raised price targets to $430–$432.&nbsp;Investors are shifting focus to&nbsp;rare earth stocks (MP, UAMY, USAR) following a landmark joint action plan between the U.S. and Japan. The two nations announced a $73 billion energy and minerals initiative, including the development of deep-sea rare earth muds near Minamitori Island.&nbsp;Azitra Inc. (AZTR):&nbsp;The stock is seeing strong pre-market action following the pricing of a $31.4 million private placement financing.ImmunityBio, Inc. (IBRX): Its cancer therapy Anktiva appeared on Macau’s latest drug list. Also, the founder has flagged early immune activation data from an Anktiva study.Other tickers trending on&nbsp;Stocktwits&nbsp;at the time of writing included Firefly Aerospace (FLY), AppLovin Corp (APP), and Qualcom (QCOM).&nbsp;On earnings radar, watch out for quarterly reports from Milestone Scientific (MIST), XPeng (XPEV), and Zegna (ZGN) before the bell today.For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Take A Breather Ahead Of Massive Options Expiry: Why SMCI, NVDA, TSLA, UAMY, IBRX Are Keeping Traders Engaged Today

Data from Stocktwits indicated that retail sentiment remains bearish on SPY and QQQ. 

Equity

Data from Stocktwits indicated that retail sentiment remains bearish on SPY and QQQ. 


<ul class="summary-bullets"><li>Executive chairman Patrick Soon-Shiong highlighted early immune activation data from an Anktiva study.</li><li>Anktiva was also added to Macau’s drug list and included in updated NCCN guidelines for papillary bladder cancer.</li><li>ImmunityBio has resubmitted its FDA application for label expansion, while advancing lung cancer trials and expanding global approvals.</li></ul>Shares of ImmunityBio, Inc. (IBRX) posted modest gains in premarket trading on Friday after executive chairman and founder Patrick Soon-Shiong flagged early immune data from an Anktiva study, adding to momentum from recent regulatory and global developments.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> has gained over 5% this week, snapping a two-week losing streak that had erased nearly 15% of its value.<h2 class="st-heading-2">Early Anktiva Data Shows Immune Activation</h2>Soon-Shiong said in a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2034892413802545271">post on X</a> that initial analysis from the first 20 subjects showed immune activation with Anktiva in combination with the company’s adenovirus-based cancer vaccine. The trial has enrolled 138 patients randomized to the combination or placebo. Data generated by the U.S. National Cancer Institute team showed confirmation of Anktiva’s immune-stimulating effect on absolute lymphocyte count.He added that baseline lymphocyte levels decline with age but appear to increase with Anktiva, citing research linking low levels to reduced lifespan. Soon-Shion also added that cancer vaccine trials are ongoing.<h2 class="st-heading-2">Anktiva Gains Macau Listing, NCCN Backing</h2>The update comes as Anktiva was added to Macau’s latest&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-snap-losing-streak-anktiva-macau-drug-list/cZ3XLBrRIhU">approved drug</a> list as a bladder cancer treatment. The inclusion places it alongside therapies from Bristol Myers Squibb, Eli Lilly, Vertex Pharmaceuticals, Gilead Sciences and Moderna.In the U.S., the National Comprehensive Cancer Network (NCCN) added Anktiva with BCG as an “other recommended” option for papillary bladder cancer that no longer responds to BCG, expanding its use beyond carcinoma in situ.<h2 class="st-heading-2">Anktiva Pipeline Expands With Strong Data</h2>ImmunityBio has resubmitted its application to expand Anktiva’s label to papillary bladder cancer after a prior refusal-to-file. In the Phase 2/3 Quilt 3.032 study, 58.2% of patients remained cancer-free at 12 months, while more than 80% avoided bladder removal surgery over three years, according to the company.The therapy is also being studied in lung cancer, with two pivotal trials underway, and has received authorizations in the U.K., Europe and Saudi Arabia.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IBRX slid to ‘bearish’ from the ‘extremely bullish’ zone over the past three months amid over a 300% surge in message volumes over the same period.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_ba9f17d55e.webp" alt="ibrx ss.png" width="963" height="143"><figcaption>IBRX sentiment and message volume as of March 20 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/ActionCuresFear/message/648063131">said</a>, The market prices a bladder cancer drug. NCI just showed data proving it works on immune decline in people without cancer.”<stembedurl>https://stocktwits.com/ActionCuresFear/message/648063131</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Adi121/message/648063344">said</a>, “Anktiva is heading towards becoming universal cancer vaccine! Lynch syndrome is the proof of concept!”<stembedurl>https://stocktwits.com/Adi121/message/648063344</stembedurl>IBRX stock has more than tripled over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dr. Patrick Soon-Shiong arrives at Trump National Golf Club Bedminster in Bedminster Township, N.J. on Saturday, Nov. 19, 2016. (Photo by Jabin Botsford/The Washington Post via Getty Images)

IBRX Stock Rises Premarket As Founder Flags Early Anktiva Immune Data — Macau Nod Fuels Bull Case

 Early trial data showed immune activation in initial patients, with Anktiva boosting lymphocyte levels.

<ul class="summary-bullets"><li>The therapy also gained momentum in the U.S. after NCCN added it as a treatment option for papillary bladder cancer patients unresponsive to BCG.</li><li>ImmunityBio has resubmitted its FDA application to expand Anktiva’s use, backed by clinical data showing strong cancer-free and bladder preservation rates.</li><li>The company is advancing Anktiva globally, with lung cancer trials underway and recent approvals in markets including Saudi Arabia.</li></ul>Shares of ImmunityBio, Inc. (IBRX) are set to snap a two-week losing streak after its cancer therapy Anktiva appeared on Macau’s latest drug list, adding to fresh momentum from a U.S. guideline expansion.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> has gained over 5% this week, snapping a two-week losing streak that had erased nearly 15% of its value.<h2 class="st-heading-2">Anktiva Added To Macau Approved List</h2>Anktiva, which is available under the generic name Nogapendekin alfa, is an immunotherapy that helps activate the body’s immune system to better fight cancer. It is approved in the U.S. for use with standard BCG treatment in patients with a type of bladder cancer that no longer responds to BCG, including those with or without certain tumor growths.The Macau filing, with data as of March, lists Anktiva as a bladder cancer treatment, identifying Nogapendekin alfa as its active ingredient and noting it is given as an injection for bladder cancer. The list also includes therapies approved by regulators such as the U.S. Food and Drug Administration (FDA), China’s National Medical Products Administration (NMPA), and the European Medicines Agency (EMA).Anktiva’s inclusion places it alongside a roster of globally approved therapies from major drugmakers, including Bristol Myers Squibb, Eli Lilly, Vertex Pharmaceuticals, Janssen, Gilead Sciences, and Moderna, positioning it among established treatments across oncology and specialty care.<h2 class="st-heading-2">NCCN Expansion Adds To Momentum</h2>The Macau development comes in the same week that Anktiva was added to updated U.S. treatment guidelines. The National Comprehensive Cancer Network (NCCN) added Anktiva, used with BCG, as an “other recommended” option for patients with papillary bladder cancer that no longer responds to BCG and has not spread into muscle tissue.Earlier versions of the guidelines had included the therapy only for carcinoma in situ. The update expands the potential patient population under clinical guidance, even as the indication is not yet formally approved by the FDA.<h2 class="st-heading-2">Anktiva Seeks Label Expansion</h2>ImmunityBio is seeking to expand Anktiva’s label to include papillary bladder cancer and has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-declines-immunitybio-resubmits-anktiva-application-to-fda/cZdVj9URIIL">resubmitted</a> its supplemental biologics license application to the FDA after previously receiving a refusal-to-file letter. The filing includes additional data requested by the agency, including updated efficacy results and long-term follow-up.Clinical data from the Phase 2/3 Quilt 3.032 study showed that 58.2% of patients remained cancer-free at 12 months, while more than 80% avoided bladder removal surgery over a three-year follow-up period, according to the company.<h2 class="st-heading-2">Global Push For Anktiva Grows</h2>Beyond bladder cancer, ImmunityBio is advancing Anktiva in lung cancer, with two pivotal trials underway in first-line and second-line non-small cell lung cancer. The company said multiple countries have expressed interest in the program as it explores broader regulatory pathways.The therapy has already received authorizations in the U.K., Europe and Saudi Arabia. In January, Saudi regulators granted approvals covering both bladder cancer and metastatic non-small cell lung cancer, including use in combination with checkpoint inhibitors.ImmunityBio said product shipments are ready to begin for a Saudi launch of Anktiva for bladder cancer, following regulatory approvals, and that it has partnered with regional distributors to expand access across the Middle East and North Africa.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IBRX slid to ‘bearish’ from the ‘extremely bullish’ zone over the past three months amid over a 300% surge in message volumes over the same period.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_ba9f17d55e.webp" alt="ibrx ss.png" width="963" height="143"><figcaption>IBRX sentiment and message volume as of March 20 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/cyberInvest/message/648013012">said</a>, “Macau - China. I’d say that’s kinda global. And unstoppable.”<stembedurl>https://stocktwits.com/cyberInvest/message/648013012</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/cyberInvest/message/648034961">said</a>, “with NMPA - Macau - China approval apparent, FDA needs to get with it. This level of disfunction is a national embarrassment. China approves before US for a US company??? This is like a Saturday Night Live skit.”<stembedurl>https://stocktwits.com/cyberInvest/message/648034961</stembedurl>IBRX stock has more than tripled over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IBRX Stock Set To Snap 2 Weeks In Red: Anktiva Joins Global Blockbusters On Macau Drug List 

IBRX Stock - Anktiva, an immunotherapy for bladder cancer, was listed in Macau’s March filing alongside globally approved drugs from major pharma players.

Anktiva, an immunotherapy for bladder cancer, was listed in Macau’s March filing alongside globally approved drugs from major pharma players.

ImmunityBio (NASDAQ:IBRX) Shares Up 3%  - Should You Buy?

ImmunityBio (NASDAQ:IBRX) Stock Price Up 3% - Here's Why...

ImmunityBio (NASDAQ:IBRX) Stock Price Up 4.3% - Here's Why

ImmunityBio (NASDAQ:IBRX) Shares Up 4.3% - Should You Buy...

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

With 132M shares short and 100% utilization, traders are betting on a massive, rapid breakout as trapped short sellers look for an exit.

Strategic partnership reports for local manufacturing in Riyadh signal significant international validation and revenue potential in the MENA region.

Investors are closely watching new federal cancer vaccine initiatives and potential federal funding that could drastically accelerate treatment adoption.

Recent regulatory approvals in Macau provide a critical beachhead for expansion into broader Asian markets and China.

IBRX
ImmunityBio Inc

Feed

News

Sentiment

Fundamentals

Info

Latest IBRX News

IBRXImmunityBio Inc